Clarity Pharmaceuticals' prostate-cancer diagnostic could be highly differentiated from peers if its Phase 3 trial delivers on sensitivity and specificity, Bell Potter analysts say in a note. They tell clients that revenue timing remains highly uncertain and contingent on multiple factors, but that the Australia-listed clinical-stage radiopharmaceutical company looks to be well funded into FY 2025 and should be self-funding from FY 2026. Bell Potter cuts the stock's target price 7.1% to A$1.30 but maintains a speculative buy rating. ([email protected]; @StuartLCondie)
- Forums
- ASX - By Stock
- Ann: Positive Guidance from FDA on Phase 3 Prostate Cancer Trial
Clarity Pharmaceuticals' prostate-cancer diagnostic could be...
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CU6 (ASX) to my watchlist
|
|||||
Last
$7.37 |
Change
-0.130(1.73%) |
Mkt cap ! $2.327B |
Open | High | Low | Value | Volume |
$7.60 | $7.60 | $7.31 | $5.165M | 697.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 135 | $7.35 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$7.40 | 4649 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 135 | 7.350 |
3 | 8041 | 7.320 |
2 | 2316 | 7.310 |
6 | 24792 | 7.300 |
2 | 1870 | 7.290 |
Price($) | Vol. | No. |
---|---|---|
7.400 | 4649 | 2 |
7.410 | 3059 | 2 |
7.420 | 5131 | 1 |
7.430 | 21962 | 2 |
7.440 | 5131 | 1 |
Last trade - 16.10pm 11/09/2024 (20 minute delay) ? |
Featured News
CU6 (ASX) Chart |